PreveCeutical Medical Inc. News Releases

PreveCeutical Adopts Semi-Annual Financial Reporting

Wed, 01 Apr 2026 16:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi-annual financial reporting framework....

PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Mon, 30 Mar 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.Dr. Pruthi is an accomplished physician-scientist and executive with more than 20...

BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Thu, 12 Mar 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company. Dr. Pruthi, a...

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

Wed, 25 Feb 2026 03:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs...

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Mon, 09 Feb 2026 03:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the...

PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology

Thu, 04 Dec 2025 07:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprietary technologies aimed at addressing...

PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement

Wed, 26 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, October 20, 2025 and November 20, 2025, the previously announced plan of...

PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 12:26:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative...

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.

Thu, 20 Nov 2025 07:00:00 -0500

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing its previously announced plan of arrangement (the...

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Thu, 30 Oct 2025 07:00:00 -0400

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private...